ReviewCurrent treatment options in gastroenterology2020
Multi-Target Stool DNA Testing for Colorectal Cancer Screening: Emerging Learning on Real-world Performance.
Review in Current treatment options in gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 35 citations in OpenAlex.
- Factors Associated with Advanced Adenoma Detection by Colonoscopy After Negative Multitarget Stool DNA Testing.Digestive diseases and sciences · 2026Observational
- Diagnostic Potential of Exosomes in Colorectal Cancer: Current Advances and Future Perspectives.Molecules (Basel, Switzerland) · 2026Review
- A hybrid molecular-imaging model for high-accuracy early colorectal cancer diagnosis.Journal of gastrointestinal oncology · 2026Article
- Association Between Spanish-Language Patient Navigation and Adherence to Multi-Target Stool DNA Testing Among Spanish-Speaking Patients at Sanitas Medical Center.Journal of cancer education : the official journal of the American Association for Cancer Education · 2025Article
- Multitarget Stool DNA Testing for Colorectal Cancer Screening in Clinical Practice.The American journal of gastroenterology · 2025Article
- Machine Learning-Enabled Non-Invasive Screening of Tumor-Associated Circulating Transcripts for Early Detection of Colorectal Cancer.International journal of molecular sciences · 2025Article
- Adherence to multi-target stool DNA testing for colorectal cancer screening in the United States.International journal of colorectal disease · 2025Article
- Colorectal Cancer: Risk Factors, Novel Approaches in Molecular Screening and Treatment.International journal of molecular and cellular medicine · 2025Review
- Review
- Fecal microbial biomarkers combined with multi-target stool DNA test improve diagnostic accuracy for colorectal cancer.World journal of gastrointestinal oncology · 2023Article
- Optimization of screening strategies for colorectal cancer based on fecal DNA and occult blood testing.European journal of public health · 2023Article
- Real-world application of a fast stool DNA test for colorectal cancer screening in primary screening positive population.Cancer medicine · 2023Article
- Endoscopists' recommendations after a false positive multitarget stool DNA test: results from a multicenter study.iGIE : innovation, investigation and insights · 2023Article
- Potential prognostic and predictive value of UBE2N, IMPDH1, DYNC1LI1 and HRASLS2 in colorectal cancer stool specimens.Biomedical reports · 2023Article
- Rates of Follow-up Colonoscopy After a Positive Stool-Based Screening Test Result for Colorectal Cancer Among Health Care Organizations in the US, 2017-2020.JAMA network open · 2023Article
- Analysis of blood markers for early colorectal cancer diagnosis.Journal of gastrointestinal oncology · 2022Article
- Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research.Leukemia · 2022Review
- Cross-cultural validation of stool Based Colorectal cancer screening methods in the North West of Iran.Annals of medicine and surgery (2012) · 2022Article
- Novel Diagnostic Biomarkers in Colorectal Cancer.International journal of molecular sciences · 2022Review
- Epigenetic Alterations in the Gastrointestinal Tract: Current and Emerging Use for Biomarkers of Cancer.Gastroenterology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewMulti-target stool DNA (MT-sDNA) was approved in 2014 for use in screening average-risk patients for colorectal cancer (CRC). Here, we highlight recent literature from post-market studies to provide an update on clinical use and utility not possible from pre-approval studies. RECENT
findingsMT-sDNA has been included in major society guidelines as an option for colorectal cancer screening, and has seen exponentially increasing use in clinical practice. MT-sDNA appears to be attracting new patients to CRC screening, and patient adherence to diagnostic colonoscopy after a positive MT-sDNA test is high. Approximately two-thirds of these patients are found to have colorectal neoplasia (CRN), 80% of whom have at least one right-sided lesion; 1 in 3 will have advanced CRN. High yield of CRN is due not only to post-screening increase in probability but also likely improved endoscopist attention. In those with a negative high-quality colonoscopy after positive MT-sDNA test ("false positive MT-sDNA"), further interventions do not appear to be necessary. SUMMARY: MT-sDNA is a promising tool to improve rates and quality of CRC screening. Further investigation should examine MT-sDNA performance in populations at increased risk for CRC, and as an interval test after colonoscopy to detect potentially missed lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.